Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
复制标题
DOI：
10.1007/s11060-018-2825-5
复制
发表时间：
2018-07-01
影响因子：
3.9
通讯作者：
Matsumura, Akira
中科院分区：
文献类型：
--
作者：
Matsuda, Masahide;Ishikawa, Eiichi;Matsumura, Akira
肿瘤血管生成因其作为脑肿瘤鉴别诊断的重要标志物和新的治疗靶点而受到越来越多的关注。前列腺特异性膜抗原（PSMA）在某些肿瘤的新生血管内皮中表达，在肿瘤细胞或正常血管内皮中很少或不表达。本研究旨在探讨PSMA在各种脑肿瘤肿瘤新生血管评价中的潜力，以及利用Zr-89-Df-IAB2M (anti-PSMA minibody) PET显像检测PSMA在脑肿瘤中表达的可能性。采用PSMA抗体免疫组化染色，对脑胶质瘤、转移性脑瘤、原发性中枢神经系统淋巴瘤（PCNSL）、放射性坏死等83例组织标本进行分析。Zr-89-Df-IAB2M PET扫描在3例复发的高级别胶质瘤或转移性脑肿瘤患者中进行。PSMA在高级别胶质瘤和转移性脑肿瘤的血管内皮中高表达，而PSMA在PCNSL和放射性坏死的血管内皮中低表达。用Zr-89-Df-IAB2M进行PET显像，可以清楚地看到PSMA在高级别胶质瘤和转移性脑瘤中的表达。此外，我们还观察到肿瘤标本中Zr-89-Df-IAB2M摄取程度与PSMA表达水平呈正相关趋势。使用Zr-89-Df-IAB2M对PSMA进行PET成像可能在PCNSL或放射性坏死的高级别胶质瘤鉴别诊断以及预测治疗效果和评估贝伐单抗治疗对高级别胶质瘤的治疗反应方面具有潜在价值。
Tumor angiogenesis has attracted increasing attention because of its potential as a valuable marker in the differential diagnosis of brain tumors as well as a novel therapeutic target. Prostate-specific membrane antigen (PSMA) is expressed by the neovasculature endothelium of some tumors, with little to no expression by the tumor cells or normal vasculature endothelium. The aim of this study was to investigate the potential of PSMA for the evaluation of the tumor neovasculature of various brain tumors and the possibility of detecting PSMA expression in brain tumors using PET imaging with Zr-89-Df-IAB2M (anti-PSMA minibody). Eighty-three tissue specimens including gliomas, metastatic brain tumors, primary central nervous system lymphomas (PCNSL), or radiation necroses were analyzed by immunohistochemical staining with PSMA antibody. Zr-89-Df-IAB2M PET scans were performed in three patients with recurrent high-grade gliomas or metastatic brain tumor. PSMA was highly expressed in the vascular endothelium of high-grade glioma and metastatic brain tumor, whereas PSMA was poorly expressed in the vascular endothelium of PCNSL and radiation necrosis. PSMA expression in high-grade gliomas and a metastatic brain tumor was clearly visualized by PET imaging with Zr-89-Df-IAB2M. Furthermore, a trend toward a positive correlation between the degree of Zr-89-Df-IAB2M uptake and PSMA expression levels in tumor specimens was observed. PET imaging of PSMA using Zr-89-Df-IAB2M may have potential value in the differential diagnosis of high-grade glioma from PCNSL or radiation necrosis as well as in the prediction of treatment efficacy and assessment of treatment response to bevacizumab therapy for high-grade glioma.